| Name | 2',2'-Difluoro-2'-deoxyuridine |
|---|---|
| Synonyms |
Uridine, 2'-deoxy-2',2'-difluoro
1-(2-Deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)-4-hydroxy-2(1H)-pyrimidinone dFdU|||2',2'-Difluoro-2'-deoxyuridine 2',2'-DIFLUORO-2'-DEOXYURIDINE(Gemcitabine impurity) 1-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)pyrimidin- 2,4(1H,3H)-dione (2′-deoxy-2′,2′-difluorouridine) 1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione Uridine,2'-deoxy-2',2'-difluoro 2',2'-Difluorodeoxyuridine 2′,2′-difluorodeoxyuridine 1-((2R,4R,5R)-3,3-difluoro Gemcitabine Impurity C 1-(2-Deoxy-2,2-difluoro-beta-D-erythro-pentofuranosyl)pyrimidin-2,4(1H,3H)-dione (2'-Deoxy-2',2'-difluorouridine) Gemcitabine Metabolite 2',2'-DIFLUORO-2'-DEOXYURIDINE 2'-Deoxy-2',2'-difluoro-D-uridine Gemcitabine impurity C 2'-Deoxy-2',2'-difluorouridine Gemcitabine Dione Impurity 1-[(2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-2-tetrahydrofuryl]pyrimidine-2,4(1H,3H)-dione 2'-deoxy-2',2'-difluorouridine 1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione Gemcitabine impurity 6/2',2'-Difluoro-2'-Deoxy Uridine 1-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)pyrimidin-2,4(1H,3H)-dione (2′-deoxy-2′,2′-difluorouridine) (β-uridine) 2'-deoxy-2',2'-fluorouracil nucleoside 1-(2-Deoxy-2,2-difluoro-beta-D-erythro-pentofuranosyl)pyrimidin-2,4(1H,3H)-dione (2'-Deoxy-2',2'-dif Uridine Impurity 4 (2',2'-Difluoro-2'-Deoxy Uridine) 2Deoxy-22difluorouridine |
| Description | 2′,2′-Difluorodeoxyuridine (dFdU) is the main metabolite of Gemcitabine (HY-17026). 2′,2′-Difluorodeoxyuridine causes a concentration- and schedule- dependent radiosensitising effect in vitro[1]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.7±0.1 g/cm3 |
|---|---|
| Melting Point | 147-149ºC |
| Molecular Formula | C9H10F2N2O5 |
| Molecular Weight | 264.183 |
| Exact Mass | 264.055786 |
| PSA | 104.55000 |
| LogP | -0.53 |
| Index of Refraction | 1.587 |
| Storage condition | -20°C Freezer |
|
~94%
114248-23-6 |
| Literature: ALIOS BIOPHARMA, INC.; Beigelman, Leonid; Wang, Guangyi; Smith, David Bernard; Deval, Jerome; Prhavc, Marija Patent: US2013/165400 A1, 2013 ; Location in patent: Paragraph 0420; 0421 ; |
|
~91%
114248-23-6 |
| Literature: Chou; Heath; Patterson; Poteet; Lakin; Hunt Synthesis, 1992 , # 6 p. 565 - 570 |
|
~%
114248-23-6 |
| Literature: US2013/165400 A1, ; |
|
~%
114248-23-6 |
| Literature: US2013/165400 A1, ; |
|
~%
114248-23-6 |
| Literature: Journal of Organic Chemistry, , vol. 53, # 11 p. 2406 - 2409 |
| Precursor 4 | |
|---|---|
| DownStream 0 | |